The global diabetes crisis is deepening. According to the International Diabetes Federation’s 2024 Diabetes Atlas, 589 million adults—1 in 9 people worldwide—live with the disease today. By 2050, that number is expected to rise to 853 million. In 2024 alone, diabetes caused 3.4 million deaths—one every nine seconds—and consumed over USD 1 trillion in health expenditures, a staggering 338% increase in just 17 years. If trends continue, that number will exceed USD 1.054 trillion by 2045.
This “silent epidemic” has inflicted pain and suffering on an unimaginable scale. But for pharmaceutical giants, insurance firms, and private hospitals, diabetes represents a reliable and lucrative revenue stream. Under the dominant capitalist model—largely shaped by corporate healthcare in the U.S. and Europe—treatment, not cure, is the business. Managing diabetes is more profitable than eradicating it. In this context, illness itself has been commodified.
But this model is facing disruption—from China.
In what could be a historic scientific breakthrough, Chinese researchers have developed a method to reverse both Type 1 and Type 2 diabetes using stem cell therapy. Using induced pluripotent stem cell (iPSC) technology, scientists at Tianjin First Central Hospital have reprogrammed a patient’s fat cells to behave like embryonic stem cells. These are then turned into insulin-producing islet cells and implanted under the anterior rectus sheath in the abdomen. Once inside the body, they begin to regulate blood sugar levels naturally, mimicking the function of a healthy pancreas.
The results have been astounding. Patients with Type 1 diabetes were able to stop insulin entirely within 75 days. Type 2 diabetes patients took just 11 weeks. The European Medical Journal hailed it as a milestone in diabetes treatment.
China’s National Medical Products Administration (NMPA) is now fast-tracking further clinical trials, with hopes of addressing this epidemic on a global scale within the next three years. If successful, this innovation could revolutionize healthcare by reducing dependency on insulin, daily monitoring devices, and lifelong medication.
More importantly, it could threaten the core business model of the global pharmaceutical industry—a system that thrives on perpetual treatment rather than cure.
This medical leap didn’t happen by accident. It’s the result of China’s deliberate policy decisions and strategic investments in public health and medical science. Under the leadership of the Communist Party of China (CPC), the country has prioritized people-centered development in healthcare. The “Shanghai Integration Model” (SIM), for example, bridges public health initiatives with research-driven medical services, resisting the commercialization and privatization that dominate Western healthcare systems.
China's public universities offer medical and health sciences programs grounded in the ethos of public welfare over profit. These institutions focus on treating curable and preventable diseases—not on monetizing them. The success of this model can be seen in breakthroughs related to diabetes, AIDS, obesity, and more.
In contrast, while China channels resources into science, medicine, and public health, the United States and its allies invest heavily in arms, surveillance, and war. The West’s neoliberal model, built on corporate lobbying and privatized care, puts profits above patients. This is most visible in their healthcare systems, where life-saving treatments are often inaccessible to the poor and uninsured, and public health remains subordinate to shareholder value.
Amid growing anti-China propaganda in the Western media, the contrast between the two development models could not be starker. One prioritizes militarism, control, and corporate profits; the other centers on public health, human dignity, and scientific progress.
It is time we recognize and defend China’s model of people-driven innovation. In a world wracked by disease, war, and inequality, China's approach to healthcare offers an inspiring alternative. It reasserts the principle that science should serve humanity—not the stock market.
If we are to create a world that values health, life, and collective progress, then we must reject the hypocrisy of Western healthcare systems and embrace the possibilities that arise when medical knowledge is used not for profit, but for the public good.
One would think that all governments would prioritize people and their health over profit - this is the collective good when resources are pooled and directed (where taxes should go).
ReplyDelete